CL2021001123A1 - Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3. - Google Patents
Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3.Info
- Publication number
- CL2021001123A1 CL2021001123A1 CL2021001123A CL2021001123A CL2021001123A1 CL 2021001123 A1 CL2021001123 A1 CL 2021001123A1 CL 2021001123 A CL2021001123 A CL 2021001123A CL 2021001123 A CL2021001123 A CL 2021001123A CL 2021001123 A1 CL2021001123 A1 CL 2021001123A1
- Authority
- CL
- Chile
- Prior art keywords
- arylsulfonylpyrrolecarboxamide
- derivatives
- potassium channel
- channel activators
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona compuestos novedosos que activan los canales de potasio Kv3. Los compuestos tienen la estructura Aspectos separados de la invención se refieren a composiciones farmacéuticas que comprenden dichos compuestos y el uso de los compuestos para tratar trastornos que responden a la activación de los canales de potasio Kv3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201800787 | 2018-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021001123A1 true CL2021001123A1 (es) | 2021-10-22 |
Family
ID=70327875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021001123A CL2021001123A1 (es) | 2018-10-30 | 2021-04-29 | Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3. |
Country Status (23)
Country | Link |
---|---|
US (1) | US20200131156A1 (es) |
EP (1) | EP3873891A1 (es) |
JP (1) | JP2022509416A (es) |
KR (1) | KR20210086661A (es) |
CN (1) | CN113056461A (es) |
AR (1) | AR116898A1 (es) |
AU (1) | AU2019373367A1 (es) |
BR (1) | BR112020013011A2 (es) |
CA (1) | CA3116273A1 (es) |
CL (1) | CL2021001123A1 (es) |
CO (1) | CO2021005579A2 (es) |
CR (1) | CR20210285A (es) |
DO (1) | DOP2021000081A (es) |
EA (1) | EA202190899A1 (es) |
EC (1) | ECSP21038534A (es) |
IL (1) | IL282639A (es) |
JO (1) | JOP20210091A1 (es) |
MA (1) | MA54061A (es) |
MX (1) | MX2021004935A (es) |
PE (1) | PE20211975A1 (es) |
SG (1) | SG11202104348XA (es) |
TW (1) | TW202031645A (es) |
WO (1) | WO2020089262A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023017263A1 (en) | 2021-08-10 | 2023-02-16 | Autifony Therapeutics Limited | Potassium channel modulators |
WO2024121552A1 (en) | 2022-12-06 | 2024-06-13 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100179203A1 (en) * | 2007-07-04 | 2010-07-15 | Antonio Nardi | Novel pyrazole derivatives useful as potassium channel modulators |
TW201028421A (en) * | 2009-01-15 | 2010-08-01 | Abbott Lab | Novel benzenesulfonamides as calcium channel blockers |
WO2011073276A1 (en) * | 2009-12-16 | 2011-06-23 | Evotec Ag | Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators |
WO2011073269A1 (en) * | 2009-12-16 | 2011-06-23 | Evotec Ag | Piperidine aryl sulfonamide derivatives as kv1.3 modulators |
US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
FR2967674B1 (fr) * | 2010-11-23 | 2012-12-14 | Pf Medicament | Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine |
WO2013120104A2 (en) * | 2012-02-10 | 2013-08-15 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9422252B2 (en) * | 2012-05-22 | 2016-08-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
GB201521751D0 (en) * | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
GB201522179D0 (en) | 2015-12-16 | 2016-01-27 | Autifony Therapeutics Ltd | Novel compounds |
GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
-
2019
- 2019-10-29 AR ARP190103138A patent/AR116898A1/es unknown
- 2019-10-29 US US16/667,563 patent/US20200131156A1/en not_active Abandoned
- 2019-10-29 TW TW108139051A patent/TW202031645A/zh unknown
- 2019-10-30 CA CA3116273A patent/CA3116273A1/en not_active Abandoned
- 2019-10-30 KR KR1020217015490A patent/KR20210086661A/ko unknown
- 2019-10-30 EP EP19798210.1A patent/EP3873891A1/en not_active Withdrawn
- 2019-10-30 AU AU2019373367A patent/AU2019373367A1/en not_active Abandoned
- 2019-10-30 MX MX2021004935A patent/MX2021004935A/es unknown
- 2019-10-30 SG SG11202104348XA patent/SG11202104348XA/en unknown
- 2019-10-30 MA MA054061A patent/MA54061A/fr unknown
- 2019-10-30 JP JP2021547926A patent/JP2022509416A/ja active Pending
- 2019-10-30 BR BR112020013011-7A patent/BR112020013011A2/pt not_active Application Discontinuation
- 2019-10-30 CN CN201980071046.3A patent/CN113056461A/zh active Pending
- 2019-10-30 EA EA202190899A patent/EA202190899A1/ru unknown
- 2019-10-30 CR CR20210285A patent/CR20210285A/es unknown
- 2019-10-30 PE PE2021000636A patent/PE20211975A1/es unknown
- 2019-10-30 JO JOP/2021/0091A patent/JOP20210091A1/ar unknown
- 2019-10-30 WO PCT/EP2019/079587 patent/WO2020089262A1/en active Application Filing
-
2021
- 2021-04-26 IL IL282639A patent/IL282639A/en unknown
- 2021-04-28 CO CONC2021/0005579A patent/CO2021005579A2/es unknown
- 2021-04-29 DO DO2021000081A patent/DOP2021000081A/es unknown
- 2021-04-29 CL CL2021001123A patent/CL2021001123A1/es unknown
- 2021-05-28 EC ECSENADI202138534A patent/ECSP21038534A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3873891A1 (en) | 2021-09-08 |
ECSP21038534A (es) | 2021-06-30 |
WO2020089262A1 (en) | 2020-05-07 |
CA3116273A1 (en) | 2020-05-07 |
PE20211975A1 (es) | 2021-10-05 |
JOP20210091A1 (ar) | 2023-01-30 |
TW202031645A (zh) | 2020-09-01 |
SG11202104348XA (en) | 2021-05-28 |
CN113056461A (zh) | 2021-06-29 |
IL282639A (en) | 2021-06-30 |
CO2021005579A2 (es) | 2021-05-10 |
AR116898A1 (es) | 2021-06-23 |
KR20210086661A (ko) | 2021-07-08 |
DOP2021000081A (es) | 2021-07-30 |
CR20210285A (es) | 2021-09-16 |
AU2019373367A1 (en) | 2021-05-27 |
MA54061A (fr) | 2021-12-15 |
JP2022509416A (ja) | 2022-01-20 |
EA202190899A1 (ru) | 2021-08-19 |
MX2021004935A (es) | 2021-06-08 |
BR112020013011A2 (pt) | 2021-05-04 |
US20200131156A1 (en) | 2020-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
DOP2019000040A (es) | Compuestos de pirrolizina sustituidas y usos de los mismos | |
CO2018008707A2 (es) | Inhibidores de la proteína quinasa 1 que interactúa con el receptor | |
DOP2017000298A (es) | Reguladores de nrf2 | |
CL2017001124A1 (es) | Agentes inmunomoduladores | |
BR112018006259A2 (pt) | "adjunto compressível com estruturas de suporte intermediárias" | |
CL2018003265A1 (es) | Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
CO2019012767A2 (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
CO2018003452A2 (es) | Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso | |
CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
CL2019001736A1 (es) | Polimorfos. | |
CL2015002083A1 (es) | Composiciones herbicidas sinergicas | |
CL2019003430A1 (es) | Tratamiento conjunto antineoplásico. | |
CL2019001737A1 (es) | Polimorfos. | |
CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
CL2018001837A1 (es) | Compuestos antiproliferativos y sus composiciones farmacéuticas y usos | |
CO2020015747A2 (es) | Analogos de rapamicina y usos de los mismos | |
CL2018003121A1 (es) | Inhibidores del potenciador del homólogo zeste 2. | |
CL2021001123A1 (es) | Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3. | |
CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
ECSP18018793A (es) | Compuestos útiles para inhibir ror-gamma-t | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 |